INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement from Inspire Pharmaceuticals Inc.
INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement made by Inspire Pharmaceuticals Inc.
The Rho kinase inhibitor interferes with the actin cytoskeleton of the trabecular meshwork to lower intraocular pressure (IOP).
This placebo-controlled dose-escalating trial will appraise the compound's safety, efficacy and tolerability in early stage glaucoma or ocular hypertension.
